Preliminary evaluation of long-term survival data exposed that multiple patients survived significantly much longer than historical controls. Aduro plans to release detailed results later this season.. Aduro receives $442,000 grant under QTDP system to support Listeria-based immunotherapy platform Aduro BioTech announced today that it’s been awarded two cash grants totaling approximately $442,000 under the U.S. Government’s Qualifying Therapeutic Discovery Project program. Related StoriesStudy shows rare HER2 missense mutations do not spread breast cancer on the ownCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesNew findings reveal association between colorectal tumor and melanoma medication treatmentThe QTDP was made by Congress within the Patient Safety and Affordable Care Work in March 2010.Five dosages and two dosing frequencies will be examined. Treatment duration is two weeks and may be prolonged to three. The viral load will be monitored before, during and after treatment. The study's clinical endpoints are: safety, viral load in the blood and CD4 and CD8 cell counts. The study aims to allow ABIVAX to narrow the dosage and rate of recurrence of administration for the subsequent clinical phase IIb study development planned for the second half of 2015.